Sitc 2024 Ak132. Ak132 efficiently binds to cldn18.2 and cd47, exerting antitumor effects through multiple mechanisms; Ak132 is an asymmetric bispecific antibody with a 1+1 valency, designed to simultaneously target and block cldn18.2 and cd47.

Ak132 is an asymmetric bispecific antibody with a 1+1 valency, designed to simultaneously target and block cldn18.2 and cd47. Ak132 efficiently binds to cldn18.2 and cd47, exerting antitumor effects through multiple mechanisms;